Sumatriptan: Uses, Dosage & Side Effects
Selective 5-HT1B/1D receptor agonist (triptan) for acute migraine relief
Sumatriptan is a selective serotonin (5-HT1B/1D) receptor agonist belonging to the triptan class of medications. It is used for the acute treatment of migraine attacks with or without aura. Sumatriptan works by constricting dilated cranial blood vessels and inhibiting the release of inflammatory neuropeptides, thereby relieving headache and associated symptoms such as nausea, vomiting, and sensitivity to light and sound. It is included on the WHO Model List of Essential Medicines and is one of the most widely prescribed migraine treatments worldwide.
Quick Facts: Sumatriptan
Key Takeaways
- Sumatriptan is a first-line acute treatment for moderate-to-severe migraine attacks, effective in approximately 60-70% of patients within 2 hours of oral administration.
- Take sumatriptan as early as possible during a migraine attack, but it can also work if taken during an ongoing attack. It should not be used to prevent migraine.
- The maximum oral dose is 100 mg in 24 hours; a second dose may be taken after 2 hours only if the first dose provided partial relief.
- Do not use sumatriptan if you have cardiovascular disease, uncontrolled hypertension, history of stroke, or are taking MAO inhibitors, ergotamine, or other triptans.
- Common side effects include tingling, dizziness, drowsiness, feeling of warmth, and transient chest or throat tightness. Seek immediate help for persistent chest pain.
What Is Sumatriptan and What Is It Used For?
Sumatriptan belongs to a class of medicines known as triptans, also called selective serotonin 5-HT1B/1D receptor agonists. It was the first triptan to be developed and has been available since the early 1990s. Today, it remains one of the most widely prescribed acute migraine treatments globally and is included on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its importance in global healthcare.
Migraine symptoms are thought to result from a temporary dilation and inflammation of blood vessels in the head, combined with activation of the trigeminal nerve pathway. Sumatriptan works through a dual mechanism: it binds to 5-HT1B receptors on intracranial blood vessels, causing them to constrict back to their normal size, and it binds to 5-HT1D receptors on trigeminal nerve endings, inhibiting the release of pro-inflammatory neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P. This combined action relieves the headache itself as well as associated migraine symptoms including nausea, vomiting, photophobia (sensitivity to light), and phonophobia (sensitivity to sound).
Sumatriptan is specifically indicated for the acute treatment of migraine attacks. It is not intended for the prevention of migraine (prophylaxis) and should not be taken before migraine symptoms begin. It is also not effective for other types of headache, such as tension-type headache or cluster headache (though subcutaneous sumatriptan may be used for cluster headache in some clinical settings). Clinical trials have demonstrated that oral sumatriptan 50 mg provides significant headache relief in approximately 50-60% of patients at 2 hours, with complete pain freedom achieved in about 25-30% of patients (Cochrane Systematic Review, 2014).
Sumatriptan is available in multiple formulations to suit different clinical needs. Oral tablets (50 mg) are the most commonly used form. For patients who experience severe nausea or vomiting with migraine, or for those who need faster relief, subcutaneous injection (12 mg/ml in pre-filled pens) provides more rapid onset of action, typically within 10-15 minutes. The choice of formulation depends on the severity of the migraine, the speed of relief required, and individual patient preference.
Sumatriptan is designed exclusively for treating migraine attacks once they have started. It does not cure migraine or reduce the frequency of attacks. If you experience frequent migraines (more than 4 per month), speak with your doctor about preventive treatment options.
What Should You Know Before Taking Sumatriptan?
Before taking sumatriptan, it is essential to ensure that your headache has been diagnosed as migraine by a healthcare professional. Sumatriptan should not be used for headaches that have not been properly evaluated, as some serious conditions can mimic migraine symptoms. Your doctor should confirm the diagnosis before prescribing or recommending sumatriptan. Understanding the contraindications, warnings, and precautions associated with sumatriptan helps ensure safe and effective use of this medication.
Contraindications
Sumatriptan must not be used in the following situations:
- Allergy to sumatriptan or any of the other ingredients in the medication
- Cardiovascular disease: including coronary artery disease (narrowing of the arteries), angina (chest pain), previous heart attack (myocardial infarction), or other significant heart conditions
- Peripheral vascular disease: poor blood circulation in the legs causing cramping pain when walking (intermittent claudication)
- Cerebrovascular disease: previous stroke or transient ischaemic attack (TIA, sometimes called a mini-stroke)
- Uncontrolled hypertension: sumatriptan may be suitable if your high blood pressure is mild and adequately treated, but should not be used with uncontrolled blood pressure
- Severe hepatic impairment: severe liver disease affects how the body metabolises sumatriptan
- Concurrent use of ergotamine or ergotamine-type medications (such as methysergide maleate), or any other triptan/5-HT1 receptor agonist (such as naratriptan, zolmitriptan, rizatriptan, eletriptan, or almotriptan)
- Current or recent use (within 2 weeks) of MAO inhibitors (monoamine oxidase inhibitors), a type of antidepressant
- Children and adolescents under 18 years of age (for oral formulation)
Never take sumatriptan at the same time as ergotamine-containing medicines or other triptans. Wait at least 24 hours after stopping ergotamine before taking sumatriptan, and at least 6 hours after taking sumatriptan before using ergotamine. Wait at least 24 hours between sumatriptan and other triptans.
Warnings and Precautions
Talk to your doctor before taking sumatriptan if any of the following apply to you:
- Cardiovascular risk factors: If you are a heavy smoker or use nicotine replacement therapy, particularly if you are a man over 40 years of age or a postmenopausal woman. In very rare cases, serious heart problems have occurred after taking sumatriptan in patients who had no prior signs of heart disease. If any of these risk factors apply, your doctor may wish to check your heart function before prescribing sumatriptan.
- Seizure disorders: If you have a history of epilepsy or any condition that lowers the seizure threshold, such as a head injury or alcohol dependence.
- Liver or kidney problems: These may affect how your body processes sumatriptan and may require dose adjustments.
- Sulfonamide allergy: If you are allergic to sulfonamide antibiotics, you may also be allergic to sumatriptan. If you know you have an antibiotic allergy but are unsure whether it involves a sulfonamide, consult your doctor or pharmacist before taking sumatriptan.
- Medication overuse: Frequent use of sumatriptan (more than 10 days per month) can paradoxically worsen headaches, leading to medication-overuse headache (MOH). If you find yourself needing sumatriptan increasingly often, consult your doctor, who may recommend discontinuing the medication.
Some patients experience pain or a feeling of tightness in the chest after taking sumatriptan. These sensations are typically transient and are thought to be related to muscle spasm rather than cardiac events. However, if chest symptoms are severe, do not resolve quickly, or worsen, seek immediate medical attention.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking sumatriptan.
Pregnancy: There is limited safety data regarding sumatriptan use during pregnancy. Current evidence from pregnancy registries and observational studies has not demonstrated a clear increase in the risk of birth defects. However, the available data is not sufficient to completely rule out any risk. Your doctor will discuss the benefits and risks and help you decide whether sumatriptan is appropriate during your pregnancy, weighing the impact of untreated severe migraine against the potential risks of the medication.
Breastfeeding: Sumatriptan passes into breast milk. To minimise the infant's exposure, do not breastfeed for 12 hours after taking sumatriptan. Breast milk expressed during this 12-hour period should be discarded and not given to your baby. Some breastfeeding women have reported breast pain and/or nipple pain after using sumatriptan. This pain is usually temporary and resolves within 3 to 12 hours.
Driving and Operating Machinery
Both migraine itself and treatment with sumatriptan can cause drowsiness and dizziness in some individuals. Do not drive or operate machinery if you are experiencing these effects. You are responsible for assessing whether you are fit to drive or perform tasks requiring alertness. The effects and side effects of the medication are one factor that may affect this ability.
How Does Sumatriptan Interact with Other Drugs?
Drug interactions can alter how sumatriptan works or increase the risk of serious side effects. It is important to tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take, including herbal products, dietary supplements (such as vitamins, iron, or calcium), and over-the-counter medications. Below is an overview of the most clinically significant drug interactions with sumatriptan.
Major Interactions (Contraindicated)
| Drug / Drug Class | Risk | Required Washout Period |
|---|---|---|
| Ergotamine / Dihydroergotamine | Prolonged vasospasm, risk of serious cardiovascular events | Stop ergotamine 24h before sumatriptan; wait 6h after sumatriptan before ergotamine |
| Other triptans (naratriptan, zolmitriptan, rizatriptan, eletriptan, almotriptan) | Additive vasoconstriction, increased cardiovascular risk | Wait at least 24 hours between different triptans |
| MAO inhibitors (e.g., phenelzine, tranylcypromine, moclobemide) | Reduced sumatriptan metabolism, increased blood levels and toxicity | Do not take sumatriptan within 2 weeks of MAO inhibitor use |
Significant Interactions (Use with Caution)
| Drug / Drug Class | Risk | Guidance |
|---|---|---|
| SSRIs (citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) | Serotonin syndrome: restlessness, confusion, sweating, hallucinations, rapid heartbeat, muscle twitching, tremor | Seek immediate medical attention if symptoms of serotonin syndrome develop |
| SNRIs (venlafaxine, duloxetine) | Serotonin syndrome (same symptoms as with SSRIs) | Monitor closely; seek immediate help if serotonin syndrome symptoms appear |
| St. John's Wort (Hypericum perforatum) | Increased risk of serotonergic side effects | Avoid concurrent use if possible |
| Lithium | Increased risk of serotonin syndrome symptoms | Monitor for serotonergic symptoms; consult your doctor |
Serotonin syndrome is a potentially life-threatening condition caused by excess serotonin activity. Symptoms include agitation, confusion, rapid heartbeat, elevated blood pressure, dilated pupils, diarrhoea, muscle twitching, excessive sweating, and tremor. If you experience any of these symptoms while taking sumatriptan with an SSRI, SNRI, or other serotonergic medication, seek emergency medical care immediately.
Safe combinations: Sumatriptan can be safely used alongside simple analgesics such as paracetamol (acetaminophen), aspirin, and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen. In fact, combining sumatriptan with an NSAID may provide better migraine relief than either medication alone, according to published evidence.
What Is the Correct Dosage of Sumatriptan?
Always take sumatriptan exactly as described in the patient information leaflet or as directed by your doctor or pharmacist. If you are unsure, ask your doctor or pharmacist. It is best to take sumatriptan as early as possible during a migraine attack, although it can also be effective when taken during an ongoing attack. Sumatriptan is a treatment for acute migraine; it should not be taken to prevent migraine attacks.
Adults (18-65 years)
Standard Oral Dose
The recommended starting dose is one 50 mg tablet, swallowed whole with water, at the onset of migraine symptoms. Your doctor may prescribe a higher starting dose of 100 mg if 50 mg has proven inadequate in previous attacks. The maximum oral dose is 100 mg in any 24-hour period.
Subcutaneous Injection
For subcutaneous injection, the recommended dose is 6 mg (0.5 ml of 12 mg/ml solution) administered using a pre-filled injection pen. A second 6 mg injection may be administered if symptoms recur, provided at least 1 hour has elapsed since the first injection. The maximum injectable dose is 12 mg in 24 hours.
If symptoms return after initial relief: If your migraine symptoms improve after the first dose but later return, you may take a second 50 mg tablet. You must wait at least 2 hours between the first and second oral dose. Do not exceed 100 mg (oral) in 24 hours.
If the first dose has no effect: Do not take a second tablet or any other sumatriptan formulation for the same migraine attack. The lack of response may indicate that you do not have migraine or that sumatriptan is not effective for your particular headache. You may take other pain relievers such as paracetamol, aspirin, or an NSAID (e.g., ibuprofen). Sumatriptan can be used again for your next migraine attack. If sumatriptan consistently does not provide relief, consult your doctor as your diagnosis may need to be reconsidered or an alternative treatment may be more suitable.
Children and Adolescents (under 18 years)
Oral sumatriptan is not recommended for children and adolescents under 18 years of age. The safety and efficacy of oral sumatriptan have not been adequately established in this age group. Some guidelines may recommend nasal spray sumatriptan for adolescents, but this should only be used under specialist supervision.
Elderly (over 65 years)
Sumatriptan is not recommended for patients over 65 years of age. The safety and efficacy have not been sufficiently studied in this population. Elderly patients may have an increased risk of cardiovascular side effects, and migraine typically decreases in frequency with advancing age.
Missed Dose
Because sumatriptan is used on an as-needed basis for acute migraine attacks (not on a regular schedule), there is no concept of a missed dose. Take it only when you experience a migraine attack.
Overdose
Do not take more than 100 mg of oral sumatriptan within 24 hours. Taking too much sumatriptan can cause serious adverse effects. Overdose symptoms may include the same side effects described in the side effects section, but may be more severe. In clinical reports, overdose with sumatriptan has caused sedation, tremor, redness of the extremities, reduced breathing rate, and cardiovascular effects.
If you or someone else has taken more sumatriptan than recommended, or if a child has accidentally ingested the medication, contact your local poison control centre or emergency services immediately. There is no specific antidote for sumatriptan overdose; treatment is supportive and symptomatic. Patients should be monitored for at least 10 hours or until symptoms resolve.
What Are the Side Effects of Sumatriptan?
Like all medicines, sumatriptan can cause side effects, although not everyone will experience them. Most side effects are mild to moderate and resolve on their own without treatment. The frequency categories below are based on published clinical trial data and post-marketing surveillance reports from regulatory agencies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Allergic Reactions
Signs of allergic reaction including skin rash, hives (raised itchy bumps), swelling of the face, eyelids, or lips, sudden breathing difficulties, rapid heartbeat, chest tightness, or collapse. Anaphylaxis (severe allergic reaction) is very rare but requires immediate emergency treatment.
Side Effects by Frequency
Common
May affect up to 1 in 10 people
- Tingling (paraesthesia) or unusual skin sensations
- Dizziness
- Drowsiness
- Transient increase in blood pressure (shortly after taking the medication)
- Flushing or feeling of warmth
- Shortness of breath (dyspnoea)
- Nausea, vomiting
- Feeling of heaviness or muscle pain
- Sensations of pain, warmth, cold, pressure, or tightness in any part of the body including the chest and throat
- Feeling of weakness (asthenia) or fatigue
Rare
May affect up to 1 in 1,000 people
- Chest pain (non-cardiac)
Very Rare
May affect fewer than 1 in 10,000 people
- Minor disturbances in liver function test results
Frequency Not Known
Cannot be estimated from available data
- Anxiety
- Seizures (epileptic fits), involuntary movements, tremor, nystagmus (involuntary eye movements)
- Visual disturbances such as flickering, reduced vision, or vision loss (which may also be caused by the migraine itself)
- Cardiac arrhythmias (changes in heart rhythm, including faster, slower, or irregular heartbeat), angina (chest pain), or heart attack (myocardial infarction)
- Low blood pressure (hypotension)
- Raynaud's phenomenon (fingers and toes becoming white or numb)
- Ischaemic colitis (inflammation of the large intestine causing lower left abdominal pain or bloody diarrhoea), diarrhoea
- Excessive sweating (hyperhidrosis)
- Neck stiffness, joint pain (arthralgia)
- Pain or worsening of pain at a site of existing injury or inflammation
- Difficulty swallowing (dysphagia)
Feelings of tightness, pressure, or heaviness in the chest and throat are among the most commonly reported side effects of triptans, including sumatriptan. In the vast majority of cases, these sensations are not related to the heart and are believed to result from oesophageal or skeletal muscle spasm. However, because sumatriptan has vasoconstrictive properties, any persistent, severe, or worsening chest symptoms should be evaluated by a doctor to rule out cardiac causes.
Reporting Side Effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed above. You can also report side effects directly to your national medicines agency (e.g., MHRA Yellow Card Scheme in the UK, FDA MedWatch in the US, or your national regulatory authority). By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Sumatriptan?
Proper storage of sumatriptan ensures the medication remains effective and safe to use throughout its shelf life. Follow these storage guidelines:
- Temperature: Store at or below 25°C (77°F). Do not freeze.
- Packaging: Keep the tablets in their original packaging (blister pack or container) to protect from moisture and light.
- Safety: Store out of the sight and reach of children.
- Expiry date: Do not use sumatriptan after the expiry date printed on the packaging (after "EXP"). The expiry date refers to the last day of that month.
- Disposal: Do not dispose of unused medicines via wastewater or household waste. Return unused or expired medication to your pharmacy for proper disposal. This helps protect the environment.
For subcutaneous injection formulations, check the solution before use. It should be clear and colourless. Do not use if the solution appears cloudy, discoloured, or contains particles. Pre-filled injection pens should also be stored below 25°C and protected from light. Do not refrigerate or freeze the injection formulation.
What Does Sumatriptan Contain?
Understanding the complete composition of sumatriptan tablets is important, particularly if you have known allergies or intolerances to certain excipients. The exact inactive ingredients may vary slightly between different manufacturers and brands.
Active Ingredient
Each film-coated tablet contains sumatriptan 50 mg (as sumatriptan succinate). Sumatriptan succinate is the salt form used in oral formulations for improved stability and bioavailability. The injection formulation contains sumatriptan 12 mg/ml in a pre-filled injection pen for subcutaneous administration.
Inactive Ingredients (Excipients)
Tablet core: Lactose monohydrate and lactose, croscarmellose sodium, microcrystalline cellulose, magnesium stearate.
Film coating: Lactose monohydrate, mannitol, titanium dioxide (E171), triacetin, talc.
Sumatriptan tablets contain approximately 176.3 mg of lactose per tablet. If you have been told by your doctor that you have an intolerance to some sugars, consult your doctor before taking this medicine. The sodium content is less than 1 mmol (23 mg) per tablet, meaning it is essentially sodium-free.
Appearance
Sumatriptan 50 mg film-coated tablets are typically round, white tablets. The exact markings vary by manufacturer. The tablets should be swallowed whole with water and should not be crushed or chewed.
Frequently Asked Questions About Sumatriptan
Sumatriptan tablets typically begin to relieve migraine symptoms within 30 minutes of oral administration, with full effect usually reached within 1-2 hours. Subcutaneous injection works considerably faster, usually providing relief within 10-15 minutes. Sumatriptan is most effective when taken early during a migraine attack, but it can also provide relief when taken during an ongoing attack. If the first dose is effective but symptoms return, a second dose can be taken after at least 2 hours.
Yes, sumatriptan can be safely taken with paracetamol (acetaminophen), aspirin, or ibuprofen. In fact, research has shown that combining sumatriptan with an NSAID such as naproxen can be more effective than either medication alone. However, you must not combine sumatriptan with other triptans (such as naratriptan or zolmitriptan) or with ergotamine-based medications. If sumatriptan does not fully relieve your migraine, simple analgesics can be used as additional treatment.
The maximum dose of oral sumatriptan is 100 mg in any 24-hour period (typically two 50 mg tablets, with at least 2 hours between doses). You should not take a second dose if the first dose had no effect at all on the same migraine attack. For subcutaneous injection, the maximum is 12 mg (two 6 mg injections) in 24 hours. Importantly, you should not use sumatriptan on more than 10 days per month, as this may lead to medication-overuse headache, a condition where frequent use of acute migraine medication paradoxically increases headache frequency.
There is limited but growing safety data for sumatriptan use during pregnancy. Data from pregnancy registries involving thousands of exposures has not shown an increased risk of major birth defects. However, the data is insufficient to confirm complete safety, and sumatriptan should only be used during pregnancy if the potential benefit justifies the potential risk. If you are pregnant or planning to become pregnant, discuss your migraine management options with your doctor. Non-pharmacological approaches such as rest, cold compresses, and avoiding triggers may be recommended as first-line treatment during pregnancy.
Sumatriptan was the first triptan developed and remains one of the most commonly used. All triptans work through the same basic mechanism (5-HT1B/1D receptor agonism) but differ in their pharmacokinetic properties. Sumatriptan has a relatively fast onset (30 minutes oral, 10 minutes injection) but a shorter half-life, which means migraine may sometimes recur. Naratriptan has a slower onset but longer duration with fewer side effects and lower recurrence rates. Rizatriptan and eletriptan may have faster oral onset than sumatriptan. Zolmitriptan is available as a nasal spray. Frovatriptan has the longest half-life and lowest recurrence rate. Your doctor can help determine which triptan is best for your individual needs based on your migraine pattern and response.
Chest tightness, pressure, or heaviness is a recognised side effect of sumatriptan and other triptans. In most cases, these sensations are benign and are thought to be caused by oesophageal or skeletal muscle spasm rather than cardiac ischaemia. They typically resolve within minutes. However, because sumatriptan causes vasoconstriction, any chest symptoms that are severe, persistent (lasting more than a few minutes), or accompanied by shortness of breath, irregular heartbeat, arm pain, or jaw pain should be treated as a potential cardiac event. Stop taking sumatriptan and seek immediate medical attention. Inform your doctor about any chest symptoms you experience, even if they resolve quickly, so they can assess whether sumatriptan remains appropriate for you.
References and Sources
All medical information on this page is based on peer-reviewed clinical evidence, official prescribing information, and international guidelines. The following sources were used:
- European Medicines Agency (EMA). Summary of Product Characteristics - Sumatriptan. Available at: www.ema.europa.eu. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Prescribing Information - Sumatriptan Succinate Tablets. NDA 020132. Revised 2023. Available at: www.accessdata.fda.gov.
- World Health Organization (WHO). Model List of Essential Medicines - 23rd List, 2023. Geneva: WHO; 2023. Available at: www.who.int.
- Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews. 2014;(5):CD008615. DOI: 10.1002/14651858.CD008615.pub2.
- National Institute for Health and Care Excellence (NICE). British National Formulary - Sumatriptan. Available at: bnf.nice.org.uk. Accessed January 2026.
- International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. DOI: 10.1177/0333102417738202.
- Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. The Lancet. 2001;358(9294):1668-1675. DOI: 10.1016/S0140-6736(01)06711-3.
- American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice. Headache. 2019;59(1):1-18.
Editorial Team
This article was written by the iMedic Medical Editorial Team and reviewed by board-certified physicians specialising in neurology and clinical pharmacology. Our editorial process follows international standards for medical content, including the GRADE evidence framework.
iMedic Medical Editorial Team - Specialists in pharmacology, neurology, and evidence-based medicine. All content follows WHO, EMA, and FDA guidelines.
iMedic Medical Review Board - Independent panel of medical experts who verify accuracy, completeness, and adherence to current clinical evidence and international guidelines.
Evidence Level: 1A - Based on systematic reviews and meta-analyses of randomized controlled trials (Cochrane Reviews, The Lancet), combined with official regulatory prescribing information (EMA, FDA) and international guidelines (WHO, NICE/BNF).
Conflict of Interest: The iMedic editorial team has no financial relationships with pharmaceutical companies. All content is independent and unbiased.
Last reviewed: | Next review due: